|Awarded On||February 16, 2022|
|Title||EIF4A is a new therapeutic vulnerability in triple-negative breast cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Jeffrey M Rosen|
Translation of mRNA into protein represents a rate limiting step and is potential therapeutic vulnerability in cancer. The translation of cancer drivers, such as oncogenes and growth factors, is frequently regulated at the level of translation initiation and requires the activity of an RNA helicase eIF4A that facilitates the unwinding of regions of secondary structure at the 5' untranslated region of mRNAs. Many of these mRNAs have longer polypurine-rich 5' UTRs and an increased frequency of upstream open reading frames.
The development of specific eIF4A helicase inhibitor, Zotatifin, by eFFECTOR Therapeutics currently undergoing a Phase I clinical trial, therefore, represents an exciting ne...